Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy

Lee, De; Jb, Hiriart; Vergniol, Julien; Merrouche, Wassil; Bédossa, Pierre; Paradis, Valérie

doi:10.1007/s10620-017-4638-3

Cited by 92 publications

(82 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fewer studies including small cohorts have assessed the diagnostic accuracy of CAP using XL probe . The sensitivity analyses reveal that CAP measurements were significantly higher using XL probe compared with M probe in the lower grade of hepatic fat content.…”

Section: Discussionmentioning

confidence: 99%

“…The use of the XL probe equipped with CAP has been shown to reduce the failure rate in obese patients providing improvement in the use of CAP for the diagnosis of NAFLD. (34,35) Studies including NAFLD patients have reported different thresholds of CAP using M and XL probe for the grade of steatosis using liver biopsy as reference. (27,36) However, to provide a relevant quantitative threshold of CAP for the detection of hepatic steatosis, measurement using a quantitative modality should be used, and non-NAFLD controls should be included.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…An important limitation of TE is the high failure rate in obese patients, which limits the reliability of liver stiffness and steatosis measurements in a significant proportion of obese patients . Recently, the new XL probe, which can provide CAP data, was shown to reduce the failure rate for measuring fibrosis and steatosis in patients with obesity . de Lédinghen et al .…”

Section: Discussionmentioning

confidence: 99%

Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis

Tada

Kumada

Toyoda

et al. 2019

Hepatology Research

View full text Add to dashboard Cite

Aim Recently, a new method has been developed to diagnose hepatic steatosis with attenuation coefficients based on the ultrasound‐guided attenuation parameter (UGAP). We investigated whether fibrosis identified by hepatic stiffness measurements based on magnetic resonance elastography (MRE) affects attenuation coefficient measurement using UGAP for the evaluation of hepatic steatosis. Methods A total of 608 patients with chronic liver disease were analyzed. Correlations between magnetic resonance imaging‐determined proton density fat fraction (PDFF) or MRE value and attenuation coefficients were evaluated. In addition, the interaction between hepatic fibrosis and the attenuation coefficient was analyzed. Results The correlation coefficient (r) between PDFF values and attenuation coefficient values was 0.724, indicating a strong relationship. Conversely, the r between MRE values and attenuation coefficient values was −0.187, indicating almost no relationship. In the multiple regression assessment of the effect of PDFF and MRE on the attenuation coefficient based on UGAP, the P‐values for PDFF, MRE, and PDFF × MRE were < 0.001, 0.277, and 0.903, respectively. In patients with non‐alcoholic fatty liver disease (n = 169), the r between PDFF values and attenuation coefficient values was 0.695, indicating a moderate relationship. Conversely, the r between MRE values and attenuation coefficient values was −0.068, indicating almost no relationship. In the multiple regression assessment of the effect of PDFF and MRE on the attenuation coefficient based on UGAP, the P‐values for PDFF, MRE, and PDFF × MRE were <0.001, 0.948, and 0.706, respectively. Conclusion UGAP‐determined attenuation coefficient was weakly affected by liver stiffness, an indicator of hepatic fibrosis.

show abstract

“…The high failure rate in patients with NAFLD is not surprising as until recently CAP was only available on the FibroScan™ M probe. The development of CAP on the XL probe may overcome these limitations [16,17], but further validation is needed.…”

Section: Controlled Attenuation Parametermentioning

confidence: 99%

Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD

Hardy

McPherson

2017

Curr Hepatology Rep

View full text Add to dashboard Cite

Purpose of Review Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world. Invasive liver biopsy remains the gold standard method for the diagnosis and staging of NAFLD. The aim of this review is to summarize recent research regarding imagingbased assessment of NAFLD. Recent Findings Novel methods such as controlled attenuation parameter (CAP) and magnetic resonance imaging proton-derived fat fraction (MRI-PDFF) appear promising for steatosis assessment and are currently undergoing validation in NAFLD. Fibrosis can be non-invasively assessed by transient elastography (TE), which is currently the best validated test in NAFLD. MR elastography (MRE) appears very sensitive for fibrosis detection. No imaging technique can accurately detect NASH. Summary TE is inexpensive and relatively widely available and can reliably exclude advanced fibrosis in NAFLD. MRI offers the most promise for steatosis and fibrosis quantification, but further validation of these techniques is needed.

show abstract

Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy

Abstract: CAP with the XL probe is a new tool for the diagnosis of steatosis. This parameter could be useful for the diagnosis and the follow-up of obese patients.

Cited by 92 publications

References 20 publications

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis

Imaging-Based Assessment of Steatosis, Inflammation and Fibrosis in NAFLD

Contact Info

Product

Resources

About